Marina Konopleva

70.2k citations

917 papers · 30.5k indexed · 6 hit papers · h-index 94

Molecular Biology top 0.1%
Hematology top 0.01%
Oncology top 0.1%
Genetics top 0.05%
Public Health, Environmental and Occupational Health top 0.1%

Co-authors: Michael Andreeff Hagop M. Kantarjian Farhad Ravandi Courtney D. DiNardo Jörge E. Cortes Gautam Borthakur Tapan M. Kadia Naval Daver
Topics: Acute Myeloid Leukemia Research (478 papers)Chronic Myeloid Leukemia Treatments (210 papers)Acute Lymphoblastic Leukemia research (182 papers)
Cited by: Hematology Genetics Oncology
Journals: New England Journal of Medicine Journal of Biological Chemistry Journal of Clinical Investigation
Partner nations: United States Japan Canada

In The Last Decade

Marina Konopleva

878 papers receiving 30.1k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia

2018 1.2k citations Courtney D. DiNardo, Marina Konopleva et al. Blood profile →
Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction

2009 552 citations Ismael Samudio, Hagop M. Kantarjian et al. profile →
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study

2018 498 citations Courtney D. DiNardo, Hagop M. Kantarjian et al. profile →
Acute myeloid leukemia: current progress and future directions

2021 471 citations Hagop M. Kantarjian, Tapan M. Kadia et al. profile →
MDM2 inhibition: an important step forward in cancer therapy

2020 276 citations Marina Konopleva, Michael Andreeff et al. profile →
Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges

2020 243 citations Marina Konopleva, Tapan M. Kadia et al. Cancer Discovery profile →

Peers

Countries citing papers authored by Marina Konopleva

Since Specialization

Citations

This map shows the geographic impact of Marina Konopleva's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marina Konopleva with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marina Konopleva more than expected).

Fields of papers citing papers by Marina Konopleva

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marina Konopleva. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marina Konopleva. The network helps show where Marina Konopleva may publish in the future.

Co-authorship network of co-authors of Marina Konopleva

This figure shows the co-authorship network connecting the top 25 collaborators of Marina Konopleva. A scholar is included among the top collaborators of Marina Konopleva based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marina Konopleva. Marina Konopleva is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Novel Therapeutic Targets in Acute Myeloid Leukemia (AML) 2024 ·Current Oncology Reports ·(unknown),Marina Konopleva,(unknown)	17
2	Maximal Activation of Apoptosis Signaling by Cotargeting Antiapoptotic Proteins in BH3 Mimetic–Resistant AML and AML Stem Cells 2022 ·Molecular Cancer Therapeutics ·Bing Z. Carter,Po Yee Mak,Wenjing Tao,Qi Zhang,Vivian Ruvolo,Vinitha M. Kuruvilla,Xiangmeng Wang,Duncan H. Mak,Venkata Lokesh Battula,Marina Konopleva,Elias Jabbour,Paul E. Hughes,Xiaoyue Chen,Phuong K. Morrow,Michael Andreeff	11
3	DYRK1a mediates BAFF-induced noncanonical NF-κB activation to promote autoimmunity and B-cell leukemogenesis 2021 ·Blood ·Yanchuan Li,Xiaoping Xie,Zuliang Jie,Lele Zhu,Jin‐Young Yang,Chun‐Jung Ko,Tianxiao Gao,Antrix Jain,Sung Yun Jung,Natalia Baran,Marina Konopleva,Xuhong Cheng,Shao‐Cong Sun	34
4	Glutaminase Activity of L -Asparaginase Contributes to Durable Preclinical Activity against Acute Lymphoblastic Leukemia 2019 ·Molecular Cancer Therapeutics ·Wai-Kin Chan,Thomas D. Horvath,Lin Tan,Todd Link,Karine G. Harutyunyan,(unknown),Andriy Anishkin,Di Du,(unknown),(unknown),Susan B. Rempe,Sergei Sukharev,Marina Konopleva,John N. Weinstein,Philip L. Lorenzi	60
5	Assessing Metabolic Intervention with a Glutaminase Inhibitor in Real-Time by Hyperpolarized Magnetic Resonance in Acute Myeloid Leukemia 2019 ·Molecular Cancer Therapeutics ·Niki M. Zacharias,Natalia Baran,Sriram S. Shanmugavelandy,Jae-Hyuk Lee,(unknown),Prasanta Dutta,Steven W. Millward,Tianyu Cai,Christopher G. Wood,David Piwnica‐Worms,Marina Konopleva,Pratip K. Bhattacharya	22
6	Interim Analysis of a Phase II Study of the Glutaminase Inhibitor Telaglenastat (CB-839) in Combination with Azacitidine in Advanced Myelodysplastic Syndrome (MDS) 2019 ·Blood ·Veronica Guerra,Jan A. Burger,Gautam Borthakur,Elias Jabbour,Naveen Pemmaraju,Tapan M. Kadia,Guillermo Garcia‐Manero,Hagop M. Kantarjian,Marina Konopleva,Courtney D. DiNardo	11
7	Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in FLT3 -Mutant Acute Myeloid Leukemia 2018 ·Clinical Cancer Research ·Xuejie Jiang,Po Yee Mak,Hong Mu,Wenjing Tao,Duncan H. Mak,Steven M. Kornblau,Qi Zhang,Peter P. Ruvolo,Jared K. Burks,Weiguo Zhang,Teresa McQueen,Rongqing Pan,Hongsheng Zhou,Marina Konopleva,Jörge E. Cortes,Qifa Liu,Michael Andreeff,Bing Z. Carter	67
8	mTORC1 Inhibition Induces Resistance to Methotrexate and 6-Mercaptopurine in Ph+ and Ph-like B-ALL 2017 ·Molecular Cancer Therapeutics ·(unknown),(unknown),Duc Nguyen,(unknown),William Pandori,(unknown),Sharmila Mallya,Mengrou Lu,Markus Müschen,Marina Konopleva,(unknown)	11
9	Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax 2016 ·Cancer Discovery ·Joan Montero,Jason Stephansky,Tianyu Cai,Gabriel K. Griffin,Lucía Cabal‐Hierro,Katsuhiro Togami,Leah J. Hogdal,Ilene Galinsky,Elizabeth A. Morgan,Jon C. Aster,Matthew S. Davids,Nicole R. LeBoeuf,Richard M. Stone,Marina Konopleva,Naveen Pemmaraju,(unknown),Andrew A. Lane	144
10	The Dual MEK/FLT3 Inhibitor E6201 Exerts Cytotoxic Activity against Acute Myeloid Leukemia Cells Harboring Resistance-Conferring FLT3 Mutations 2016 ·Cancer Research ·Weiguo Zhang,Gautam Borthakur,Gao Chen,Ye Chen,Hong Mu,Vivian Ruvolo,K. Nomoto,Nanding Zhao,Marina Konopleva,Michael Andreeff	52
11	Reversal of Acquired Drug Resistance in FLT3 -Mutated Acute Myeloid Leukemia Cells via Distinct Drug Combination Strategies 2014 ·Clinical Cancer Research ·Weiguo Zhang,Gao Chen,Marina Konopleva,Ye Chen,Rodrigo Jácamo,Gautam Borthakur,Jörge E. Cortes,Farhad Ravandi,Abhijit Ramachandran,Michael Andreeff	42
12	Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia 2014 ·Clinical Cancer Research ·Marina Konopleva,Roland B. Walter,Stefan Faderl,Elias Jabbour,Zhihong Zeng,Gautam Borthakur,Xuelin Huang,Tapan M. Kadia,Peter P. Ruvolo,Jennie B. Feliu,Hongbo Lu,(unknown),Jan A. Burger,Michael Andreeff,Wenbin Liu,Keith Baggerly,Steven M. Kornblau,L. Austin Doyle,Elihu H. Estey,Hagop M. Kantarjian	70
13	Evaluation of Apoptosis Induction by Concomitant Inhibition of MEK, mTOR, and Bcl-2 in Human Acute Myelogenous Leukemia Cells 2014 ·Molecular Cancer Therapeutics ·Weiguo Zhang,Vivian Ruvolo,Gao Chen,Liran Zhou,William G. Bornmann,Twee Tsao,Wendy Schober,Paul D. Smith,Sylvie M. Guichard,Marina Konopleva,Michael Andreeff	30
14	BH3 Profiling Discriminates Response to Cytarabine-Based Treatment of Acute Myelogenous Leukemia 2013 ·Molecular Cancer Therapeutics ·William E. Pierceall,Steven M. Kornblau,Nicole E. Carlson,Xuelin Huang,(unknown),(unknown),Michael Elashoff,Marina Konopleva,Michael H. Cardone,Michael Andreeff	22
15	A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas 2012 ·Clinical Cancer Research ·David S. Hong,Razelle Kurzrock,Jeffrey G. Supko,Xiaoying He,Aung Naing,Jennifer J. Wheler,Donald P. Lawrence,Joseph P. Eder,Colin J. Meyer,Deborah A. Ferguson,James W. Mier,Marina Konopleva,Sergej Konoplev,Michael Andreeff,Donald Küfe,Hillard Lazarus,Geoffrey I. Shapiro,Bruce J. Dezube	197
16	Role of Peroxisome Proliferator-Activated Receptor-γ and Its Coactivator DRIP205 in Cellular Responses to CDDO (RTA-401) in Acute Myelogenous Leukemia 2010 ·Cancer Research ·Twee Tsao,Steven M. Kornblau,Stephen Safe,Julie C. Watt,Vivian Ruvolo,Wenjing Chen,Yihua Qiu,Kevin R. Coombes,Zhenlin Ju,Maen Abdelrahim,Wendy Schober,Xiaoyang Ling,Dimitris Kardassis,Colin J. Meyer,Aaron D. Schimmer,Hagop M. Kantarjian,Michael Andreeff,Marina Konopleva	39
17	Blockade of Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase and Murine Double Minute Synergistically Induces Apoptosis in Acute Myeloid Leukemia via BH3-Only Proteins Puma and Bim 2010 ·Cancer Research ·Weiguo Zhang,Marina Konopleva,Jared K. Burks,(unknown),Wendy Schober,Jer-Yen Yang,Teresa McQueen,Mien‐Chie Hung,Michael Andreeff	58
18	Mechanisms of Antileukemic Activity of the Novel Bcl-2 Homology Domain-3 Mimetic GX15-070 (Obatoclax) 2008 ·Cancer Research ·Marina Konopleva,Julie C. Watt,Rooha Contractor,Twee Tsao,David Harris,Zeev Estrov,William G. Bornmann,Hagop Kantarjian,Jean Viallet,Ismael Samudio,Michael Andreeff	215
19	Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML 2008 ·Blood ·Zhihong Zeng,Yue Shi,Ismael Samudio,Rui-Yu Wang,Xiaoyang Ling,Olga Frolova,Mark J. Levis,Joshua B. Rubin,(unknown),Elihu H. Estey,Sergej Konoplev,Michael Andreeff,Marina Konopleva	397
20	Identification of Small Molecules that Sensitize Resistant Tumor Cells to Tumor Necrosis Factor-Family Death Receptors 2006 ·Cancer Research ·Aaron D. Schimmer,Michael P. Thomas,Rose Hurren,Marcela Gronda,Maurizio Pellecchia,Gregory R. Pond,Marina Konopleva,Debbie Gurfinkel,Imtiaz A. Mawji,Ewan Brown,John C. Reed	59

About Marina Konopleva

Marina Konopleva is a scholar working on Hematology, Genetics and Oncology, having authored 917 papers that have together received 30.5k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (478 papers), Chronic Myeloid Leukemia Treatments (210 papers) and Acute Lymphoblastic Leukemia research (182 papers). The work is most often cited by research in Hematology (15.6k citations), Genetics (5.9k citations) and Oncology (7.9k citations). Marina Konopleva has collaborated with scholars based in United States, Japan and Canada. Frequent co-authors include Michael Andreeff, Hagop M. Kantarjian, Farhad Ravandi, Courtney D. DiNardo, Jörge E. Cortes, Gautam Borthakur, Tapan M. Kadia, Naval Daver, Guillermo Garcia‐Manero and Elias Jabbour. Their work appears in journals such as New England Journal of Medicine, Journal of Biological Chemistry and Journal of Clinical Investigation.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact